Orcator Oy purchased 5,892,334 shares in Eevia Health Plc through the subscription of new shares in the recent Rights issue in the Company, completed on February 20. Additionally, Orcator Oy subscribed for 25,974,026 shares through a top guarantee commitment, which the Company called upon in the rights issue. This subscription has been made without the support of subscription rights due to a delay in the transfer of shares and subscription rights to Orcator Oy from Stein Ulve, following a reorganization of his holdings of shares.
 

The price for the shares Orcator Oy subscribed for was Eurocent 0,77 per share, in line with the terms of the Rights issue for subscriptions in Sweden. Hence, the 5,892,334 shares were purchased for a sum of EUR 45,371 (c. KSEK 543 at current SEK/EUR exchange rate) and the 25,974,026 shares in the top guarantee commitment subscription was purchased for a sum of EUR 200 000 (c. MSEK 2.2) which was paid through a set off. The Company has indicated that the shares will be delivered to Orcator Oy on March 4, 2025.

Orcator Oy owned 2,946,167 shares before the purchases listed above, constituting 4.4% of the outstanding shares before the rights issue (67,055,595). Orcator Oy now owns 34,812,527 shares. The total outstanding shares in Eevia increased to 126,850,605 shares following recent rights issue. Hence, Orcator’s new holding now equals 27.4% of the Company's current outstanding shares. Due to the purchases and low subscription rate (44.6%), Orcator’s shareholding rose above 25%.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com                  

Telephone: +358 400 22 5967                                

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.

Eevia Health is a manufacturer of 100 percent organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

As a pioneering company, Eevia is developing high-value food ingredients, blended solutions, and biomaterials that significantly benefit human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.